BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 3, 2026
Home » Authors » Kim Coghill

Articles by Kim Coghill

Synthetic Blood Gains Access To $20M Equity Credit Line

June 4, 2002
By Kim Coghill

FDA Says Animal Studies Enough For Drugs To Counter Bioterrorism

June 3, 2002
By Kim Coghill
WASHINGTON - A new FDA regulation allows drugs developed as antidotes to biological and chemical warfare to gain regulatory approval based on animal studies when human efficacy trials are not ethical. (BioWorld Today)
Read More

FDA Says Animal Studies Enough For Drugs To Counter Bioterrorism

June 3, 2002
By Kim Coghill
WASHINGTON - A new FDA regulation allows drugs developed as antidotes to biological and chemical warfare to gain regulatory approval based on animal studies when human efficacy trials are not ethical. (BioWorld Today)
Read More

Biotech Officials Push Harder To Get FDA Leader Appointed

May 31, 2002
By Kim Coghill
WASHINGTON - Every now and then when a drug doesn't win FDA approval, someone in the background can be heard blaming the failure on a lack of leadership at the government agency. (BioWorld Today)
Read More

Biotech Officials Push Harder To Get FDA Leader Appointed

May 31, 2002
By Kim Coghill
WASHINGTON - Every now and then when a drug doesn't win FDA approval, someone in the background can be heard blaming the failure on a lack of leadership at the government agency. (BioWorld Today)
Read More

Study Reports Most New Drug Approvals Based On Old Science

May 30, 2002
By Kim Coghill

Study Reports Most New Drug Approvals Based On Old Science

May 30, 2002
By Kim Coghill

Lilly ICOS's Cialis Demonstrates Efficacy In ED At 24, 36 Hours

May 29, 2002
By Kim Coghill
Lilly ICOS LLC's proposed drug for erectile dysfunction apparently gives men the ability to achieve an erection some 24 to 36 hours after taking it. Comparatively, Pfizer Inc.'s blockbuster drug Viagra offers only an eight-hour window. (BioWorld Today)
Read More

Lilly ICOS's Cialis Demonstrates Efficacy In ED At 24, 36 Hours

May 29, 2002
By Kim Coghill
Lilly ICOS LLC's proposed drug for erectile dysfunction apparently gives men the ability to achieve an erection some 24 to 36 hours after taking it. Comparatively, Pfizer Inc.'s blockbuster drug Viagra offers only an eight-hour window. (BioWorld Today)
Read More

House, Senate Pass Bioterrorism Bill On To Bush For Signature

May 28, 2002
By Kim Coghill
Previous 1 2 … 118 119 120 121 122 123 124 125 126 … 142 143 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 2, 2026.
  • Vials, syringes, and pills

    With improved technologies, biomarkers, failed drugs may come into their own

    BioWorld
    At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...
  • Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques

    Small-molecule TREM2 agonist advances to treat Alzheimer’s

    BioWorld Science
    Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
  • Amyloid beta peptides on neurons

    Amlogenyx’s AM-805 reduces amyloid plaques in AD

    BioWorld Science
    The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for March 31, 2026
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing